Skip to main content
Premium Trial:

Request an Annual Quote

Mammogen Closes $2M Seed Round Supporting GenTRU Liquid Biopsy Tech for Breast Cancer Detection

NEW YORK – Women's health startup Mammogen said Wednesday that it has closed an oversubscribed $2 million equity financing seed round.

The proceeds will fund ongoing clinical development efforts for Mammogen's genTRU breast program, a detection assay powered by what the firm said is a proprietary RNA-based liquid biopsy platform. According to the company, the service is designed to provide noninvasive screening and reduce unnecessary breast biopsies.

Mammogen is one of three startups housed under the umbrella of a larger company called IV Bioholdings. The two other firms, LiquidLung and HepGene are described as advancing diagnostic technologies for lung disease and liver disease, respectively.

The company said that studies of its technology have "demonstrated statistical significance toward providing measurable improvement upon current standards of care" but does not list specific publications on its website.

"We are uniquely integrating data, science and the lived experiences from the patients that we serve into all ongoing product development efforts related to our flagship breast cancer program. Our objective is to detect earlier, diagnose easier, and treat more comprehensively for the nearly 100 [million] women who are currently underserved by existing standards of care," CEO Elizabeth Cormier-May said in a statement.

Beyond breast cancer, Mammogen said it is also working on a larger product pipeline that includes a variety of noninvasive prognostics and diagnostics for additional diseases that affect "some-, mostly-, or only-women."

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.